<DOC>
	<DOCNO>NCT00004181</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness allogeneic bone marrow transplantation treat patient multiple myeloma , chronic phase chronic myelogenous leukemia , agnogenic myeloid metaplasia .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Multiple Myeloma , Chronic Phase Chronic Myelogenous Leukemia , Agnogenic Myeloid Metaplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy allogeneic bone marrow transplantation ( BMT ) follow high-dose cyclophosphamide total body irradiation patient multiple myeloma , agnogenic myeloid metaplasia , chronic myelogenous leukemia first second chronic phase . - Determine efficacy BMT follow busulfan cyclophosphamide patient . - Determine toxic effect preparative regimen patient . OUTLINE : Patients stratify remission ( first v second vs third ) . Patients undergone prior radiotherapy receive cyclophosphamide IV day -6 -5 undergo total body irradiation twice day day -4 -1 . Allogeneic bone marrow infuse day 0 . Patients undergone prior radiotherapy receive oral busulfan every 6 hour day -7 -4 -6 -3 cyclophosphamide IV 2 hour day -3 -2 . Allogeneic bone marrow infuse day 0 . Patients follow day 30 90 , 6 month , annually thereafter . PROJECTED ACCRUAL : A total 20-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically proven disease one follow type transfusiondependent anemia thrombocytopenia ( le 50,000/mm^3 ) : Multiple myeloma Agnogenic myeloid metaplasia Chronic myelogenous leukemia first second chronic phase Philadelphia chromosome BCR gene rearrangement Suitable sibling bone marrow donor available PATIENT CHARACTERISTICS : Age : 15 physiologic 55 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL SGOT le 2 time normal Alkaline phosphatase less 2 time normal Renal : Creatinine le 2 mg/dL Cardiovascular : Ejection fraction normal MUGA No acute myocardial infarction within past 6 month No active angina pectoris No active congestive heart failure Pulmonary : FEV great 50 % predict DLCO least 50 % Other : HIV negative No active infection No concurrent organ damage medical problem would preclude therapy PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>